Live symbol workspace

MRK market intelligence

Chart, AI analysis, key levels, technical analysis, sentiment, and market news are grouped so the next action is always visible.

Current $120.89

Trend Flat

Sentiment Neutral

{# Only render the live technical grid when the AI analysis carries real, non-placeholder data. Sentinel payloads (data_status error/collecting, current_price 0) are handled by the Asset Intelligence Dossier below, which degrades to a calm branded empty state instead of "0%" widgets. #}

Detailed Market Analysis

Key Levels

Support

$114.85

Resistance

$126.93

Volume & Momentum

Volume

Weak

0.8x avg

Momentum

0%

Weak

Technical Analysis

HOLD

Entry $120.89

Stop $114.85

Target $126.93

RSI: 50 | Current: $120.89

Market Sentiment

50

Neutral

Stock Metrics

Daily Vol

0%

VIX Est

20

Weekly

0%

Asset Intelligence Dossier

Provider track record

Not enough scored provider calls yet for this asset.

Confidence trend

36%

▲ 6.2 pts vs previous week

Avg confidence across 8 calls in the last 7 days

What sources say

Bullish 1 article

2 Reasons to Watch MRK and 1 to Stay Cautious

Neutral 1 article

Congo Faces Surge in Ebola Cases as Key Medical Tools Run Short

Insider Trading

Refreshing insider trades from FinViz…

Technical Signals

Refreshing technical signals from FinViz…

MRK News Intelligence (6 articles)

AI-curated news influencing MRK price, sentiment, and trend

Explore All MRK News with AI Analysis

Economy

1 day, 18 hours ago

Congo Faces Surge in Ebola Cases as Key Medical Tools Run Short

Africa’s top public health official said the latest Ebola outbreak in eastern Congo is being fought without one of the …

Impact on MRK: The shortage of vaccines in the Congo Ebola outbreak may positively impact …

The latest Ebola outbreak in eastern Congo lacks a key medical tool, vaccines, which may … Medium (50%)

View full analysis →

Bloomberg 50% confidence

Economy

3 days, 17 hours ago

2 Reasons to Watch MRK and 1 to Stay Cautious

Merck has had an impressive run over the past six months as its shares have beaten the S&P 500 by …

Impact on MRK: Potentially positive price action expected

Analysis of stock market developments showing bullish sentiment. Medium (60%)

View full analysis →

Yahoo Finance 60% confidence

Economy

1 month ago

3 Reasons We Love Merck (MRK)

Over the past six months, Merck has been a great trade, beating the S&P 500 by 32%. Its stock price …

Impact on MRK: Neutral market sentiment indicated

FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence. High (94%)

View full analysis →

Yahoo Finance 94% confidence

Economy

1 month, 1 week ago

Better Pharma Dividend Stock: Novartis vs. Merck

Both are great stocks to buy in the current environment, but which one is the better bet?

Impact on MRK: The comparison between Novartis (NVS) and Merck (MRK) may lead to sector …

The article compares Novartis and Merck as dividend stocks in the pharmaceutical sector, considering their … Medium (50%)

View full analysis →

Yahoo Finance 50% confidence

Economy

1 month, 2 weeks ago

Strong Results Lifted Merck & Co (MRK) in Q4

TCW funds, an investment management company, released its “TCW Relative Value Large Cap Fund” fourth-quarter 2025 investor letter. A copy …

Impact on MRK: Neutral market sentiment indicated

FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence. High (94%)

View full analysis →

Yahoo Finance 94% confidence

Stocks

2 months ago

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme disease …

Impact on MRK: The announcement is likely to have a positive impact on Pfizer's (PFE) …

Pfizer and Valneva plan to seek regulatory approval for a Lyme disease vaccine after a … High (80%)

View full analysis →

MarketWatch 80% confidence